NYSE
BMY
Last Price
US $57.62
KEY FIGURES
MKT CAP
$117.5B
EPS
TTM
$3.56
PEG
TTM
0.49x
P/E
TTM
16.16x
P/S
TTM
2.44x
YIELD
4.35%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
39.05%
Return on equity
ROIC: 13.55%
Valuation History
16.2X
Price to Earnings
EV/EBITDA: 11.1X
Cash flow
Profit margin
2.54%
(FY vs FY)
EBITDA Y/Y
24.16%
(FY vs FY)
Cash flow Y/Y
-0.69%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $57.62
-7.31%
Default assumptions
EBITDA Multiple
Fair Value
Market $57.62
-44.85%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Bristol-Myers Squibb Company cash flow to debt ratio of 30.03% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial risk - Healthy cash flow growth.
Bristol-Myers Squibb Company's free cash flow has decreased -7.87% from $13.94G last year to $12.85G, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Bristol-Myers Squibb Company's debt to equity ratio is 2.22, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Bristol-Myers Squibb Company's debt has decreased relative to shareholder equity from 3.13 last year to 2.22 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Bristol-Myers Squibb Company has a net debt to EBITDA ratio of 2.54x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Bristol-Myers Squibb Company's interest coverage ratio of 12.25 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Bristol-Myers Squibb Company's profit margin has increased (-181.00%) in the last year from -18.53% to 15.01%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Bristol-Myers Squibb Company's short-term assets of $29.39G exceed its short-term liabilities of $23.42G
Increasing performance - ROA.
Bristol-Myers Squibb Company's return on assets of 8.41% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Bristol-Myers Squibb Company's return on equity of 39.05%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Bristol-Myers Squibb Company's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Bristol-Myers Squibb Company had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Bristol-Myers Squibb Company has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Bristol-Myers Squibb Company has a free cash flow yield of 10.94%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Bristol-Myers Squibb Company's yearly earnings has increased -178.82% since last year from $-8.95G to $7.05G, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Bristol-Myers Squibb Company's yearly revenue has decreased -0.22% since last year from $48.30G to $48.19G, signaling decreasing performance
Increasing performance - ROIC.
ROIC 13.55% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Bristol-Myers Squibb Company's 3-year revenue CAGR of 1.45% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
Bristol-Myers Squibb Company had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
Bristol-Myers Squibb Company had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Bristol-Myers Squibb Company is overvalued relative to its fair value price of 53.41 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Bristol-Myers Squibb Company has an earnings yield of 6.19%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Bristol-Myers Squibb Company is overvalued relative to its fair value price of 31.78 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Bristol-Myers Squibb Company has an EV/EBITDA ratio of 11.08x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Bristol-Myers Squibb Company has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
Bristol-Myers Squibb Company has a price-to-book ratio of 5.86x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Undervalued - P/S ratio.
Bristol-Myers Squibb Company has a price-to-sales ratio of 2.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue